Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
← catalyst calendarNCT05003986 · readout in 205 d
Sponsored by Travere Therapeutics, Inc. (industry) · TVTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
67estimated
Sites
47
Countries
Germany, Italy, Netherlands +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-12 | actual | When the study began enrolling |
| Primary completion | 2027-03-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-12 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Focal Segmental Glomerulosclerosis
- Minimal Change Disease
- Immunoglobulin A Nephropathy
- IgA Vasculitis
- Alport Syndrome
Interventions
- Drug: Sparsentan — also filed as RE-021
- Drug: Sparsentan — also filed as RE-021
- Drug: Sparsentan — also filed as RE-021
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs)
measured After the last patient has undergone the week 108 visit (Visit 15).
Urine protein/creatinine ratio (UP/C) at week 108
measured After the last patient has undergone the Week 108 visit (Visit 15)
Publications
- PMID 42384439 — linked by the registry
- PMID 40938675 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TVTX's whole pipeline · Catalyst calendar · Every registered study · What changed